Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Promacta by Novartis for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome): Likelihood of Approval
Promacta is under clinical development by Novartis and currently in Phase III for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)....